Savini


Brief Tale of a Bacteraemia by Rhodococcus equi, With Concomitant Lung Mass: What Came First, the Chicken or The Egg?


Vincenzo Savini1, Prassede Salutari2, Marco Sborgia2, Iole Mancini3, Gioviana Masciarelli1, Chiara Catavitello1, Daniela Astolfi1, Claudio D’Amario4, Giuseppe Fioritoni2 ,Antonio Spadaro2 and Domenico D’Antoni1

1Clinical Microbiology and Virology, Department of Transfusion Medicine, Spirito Santo Hospital, Pescara (Pe), Italy. 2Department of Haematology, Spirito Santo Hospital, Pescara (Pe), Italy. 3Department of Radiology and Biomedical Imaging, Spirito Santo Hospital, Pescara (Pe), Italy. 4Clinical Pathology, San Liberatore Hospital, Atri (Te), Italy.


Correspondence to: Vincenzo Savini. Clinical Microbiology and Virology, Department of Transfusion Medicine, Spirito Santo Hospital, via Fonte Romana 8, Pescara (Pe), 65100, Italy; phone: 320-6265740. E-mail: vincsavi@yahoo.it

Published: January 17, 2011
Received: November 24, 2010
Accepted: January 8, 2011
Medit J Hemat Infect Dis 2011, 3: e2011006, DOI 10.4084/MJHID.2011.006
This article is available from:http://www.mjhid.org/article/view/7098
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract
Rhodococcus equi is an uncommon Gram positive, variably acid-fast pathogen, that appears as hard to treat mostly owing to the establishment of intracellular niches. Lack of interpretive criteria for susceptibility testing may lead to under-reporting or overestimation of resistances, whereas knowledge about this pathogen’s clinical impact may be affected by erroneous phenotype-based characterization at a genus and species level.
We present the case of a bacteraemia with a concomitant lung mass in a lymphoma patient, that further highlights the emergence of rhodococcal diseases as a matter for concern in the fields of infectious diseases and haematology.


Introduction
Rhodococcus equi is a zoonotic organism that has been collected from soil, water, horses, cattle, swines and wild birds; although it is found in stools of many grazing animals, foals show a unique susceptibility to clinical disease. They usually present with a subacute to chronic purulent bronchopneumonia, complicating with abscess formation and suppurative involvment of distant sites including colon, lymph nodes and skin. The organism rarely affects other herbivores, but may cause swine granulomatous submaxillary and submandibolary lymphadenitis. In humans, it is responsible for rare, potentially fatal diseases, predominantly occurring in compromised patients with neutropenia, underlying HIV infection, lymphoma, T-cell prolymphocytic leukaemia, chronic and acute myeloid/chronic and acute lymphoblastic leukemia, chronic renal failure, end stage liver disease, lung cancer, alcoholism, diabetes mellitus, along with those undergoing splenectomy, or receiving corticosteroids and/or immunosuppressive drugs (i.e. for rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus and antineutrophil cytoplasmic antibodies positive vasculitis), solid organ transplantation (kidney, pancreas, kidney-pancreas, heart, liver, lung) and HSCT (Hematopoietic Stem Cell Transplantation). Conversely, only 10-15% of all cases happens in the apparent absence of any immune system impairment. Mortality of about 11%, 50-55%, and 20-25% is observed in immunocompetent people, AIDS (Acquired Immune Deficiency Syndrome) patients, and compromised hosts without HIV infection, respectively.[1-8]

Case report
A 54-year-old male patient suffering from refractory non-Hodgkin lymphoma with peripheral B lymphocytes, LLC type (diagnosed 6 years before), was admitted to the Haematology department of the Pescara Civic Hospital due to the onset of fever (up to 39C). Blood samples (two bioMrieux BacT/Alert aerobe bottles plus one for anaerobe organisms) were taken for culture; a second set (for only aerobes) was sent to laboratory 30 min later, then meropenem was started, without success.
After 48 h incubation, the aerobe samples were detected as positive by the instrument. Smear staining showed Gram positive coccobacilli, with cultures growing R. equi-like colonies (see below) on sheep blood agar (> 200 colony-forming units [CFU]/plate), after 72 h incubation, in ambient air, at 37C. BioMrieux Vitek2 identified the isolate as Kocuria kristinae (excellent identification, 99% certainty); anyway, Kocuria species are known to only include cocci, not coccobacilli; so, 16S RNA sequencing was performed and finally confirmed the isolate as R. equi, as expected.[8,9]
A Clinical and Laboratory Standards Institute (CLSI) disc diffusion assay [10] was performed, with the isolate showing resistance to penicillin, oxacillin, clindamycin and tetracycline, and susceptibility to all among erythromycin, ciprofloxacin, cotrimoxazole, rifampin, teicoplanin and vancomycin. Notably, due to the lack of specific inhibition zone diameter breakpoints, interpretive criteria for staphylococci were used. Again, being resistance mechanisms still unclear, the strain was prudently considered as sharing PBP (Penicillin Binding Protein) mutation with oxacillin-resistant staphylococci, then pan-β-lactam resistant. Meropenem was then replaced by vancomycin (10-day administration), which led to resolution of fever within 48 h. Blood cultures performed after 1 week from starting glycopeptide did not grow any organisms.
The patient did not have any central venous lines, and was receiving no chemotherapies at the time that the bacteraemic episode was diagnosed. Of interest, stool and sputum cultures grew R. equi, both concurrently with bacteraemia and after the patient recovered from the latter; this was perhaps due to the intracellular survival of the organism, so that vancomycin could not eradicate colonization. Notably, a cavitated left upper lobe lung nodule (Figure 1) was observed at CT (Computed Tomography) scan and surgically removed, after resolution of the bloodstream infection. The omogenated tissue grew R. equi as a pure culture (>105 CFU/ml), with all among blood, lung, stool and sputum isolates sharing the same behaviour towards drugs (genome comparison was not performed, unfortunately). Then, we wondered whether the organism moved from lung to blood, or vice versa. Finally, in spite of the well known diffusion of R. equi in livestock, the patient did not refer any contact with animals, so that the source of colonization remained unknown.



Figure 1. Patient’s lung nodule at CT scan.


Rhodococci are Gram positive organisms belonging to the group of mycolata (mycolic acid containing bacteria), that also incorporates the genera Nocardia, Gordonia, Corynebacterium, Tsukamurella, Dietzia, Williamsia, Turicella, Skermania, and Mycobacterium.[11] The name Rhodococcus was firstly used by the German botanist Wilhelm Friedrich Zopf in 1891, when classifying pigment-producing bacterial and fungal microorganisms. The genus was then redefined in 1977 to include members of the rhodochrous complex, which contained nocardioform and mycobacterial-like species. R. equi (previously Corynebacterium equi) appears as an encapsulated, non-motile, catalase-positive, CAMP test-positive, strictly aerobe, pleomorphic coccobacillus (cells can be erroneously labeled as belonging to corynebacteria and micrococci), although rhodococci may be observed as cocci on solid media and tissues, but appear as pleomorphic (with long rods or filaments, mycelial branching and rudimentary beading) in liquid cultures. R. equi grows optimally at 30oC, forming large, mucoid, irregular, salmon-pink to red colonies after 2-7 days of incubation (Figure 2). Phenotype-based misidentification as Corynebacterium sp. has been obtained by using automated methods for typing. Finally, acid-fast staining cannot discriminate the organism from mycobacteria.[7,9,12-15].



Figure 2. Colonies on chocolate agar plate (image taken from Yamshchikov AV et al. Lancet Infect Dis 2010; 10: 350-359, With the permission of the author).


R. equi was firstly isolated from foals with pyogranulomatous pneumonia in 1923, with the first human infection being diagnosed in 1967; major clinical manifestations include lung, liver, kidney, psoas muscle, subcutaneous, pelvic and brain abscesses, pneumonia (even with necrotizing cavitary lesions, pulmonary malakoplakia, mediastinal lymphadenitis, effusion/empyema, concomitant bacteraemia and disseminated infection), cutaneous wound infections, gastrointestinal ulcerations, diarrhea, meningitis, pericarditis, endocarditis, osteomyelitis, peritonitis (associated with ambulatory peritoneal dialysis) and peritoneal shunt infection, cervical adenopathy, lymphangitis, mastoiditis, endophtalmitis and sepsis. Clinical picture of low airway disease usually includes cachexia, fatigue and weight loss; these symptoms, along with the occasional and variable acid fastness of the pathogen and its predilection for causing upper-lobe cavitation, frequently lead to misdiagnosis as pulmonary tuberculosis. Due to survival inside histiocytes, diseases are commonly chronic and recurrent, with relapses occurring after brief courses of antibiotics, or during treatment.[5-8,12,13,16,17].
In this context, malakoplakia is a dense infiltration of foamy histiocytes with intracellular coccobacilli and scattered concentric basophilic inclusions called Michaelis-Gutmann bodies, which likely represent infected macrophages with ingested bacteria; although not specific to R. equi infection (Escherichia coli, Pasteurella multocida and Mycobacterium tuberculosis may cause similar pathological changes), it is frequently associated with lung illnesses by this species, in compromised hosts (Figure 3).[7]



Figure 3.
Lung tissue with intracellular coccobacillary forms (image taken from Yamshchikov AV et al. Lancet Infect Dis 2010; 10: 350-359, With the permission of the author).


The surface soil of 50-95% of horse farms shows high concentrations of the microorganism, with inhalation of infected dust particles and aerosols appearing as the main route of transmission to foals. Also, these can acquire the infection through direct inoculation of wounds and mucous membranes, as well as by metastatic dissemination to distant sites. Similarly, humans may fall ill after ingestion, inhalation or direct inoculation of bacteria into skin lesions. Man disease is in fact strongly related to livestock exposure or farming environments, although apparent contact with animals may be lacking and no clear evidence of endogenous colonization as a source for human illness exists so far. Finally, even if nosocomial and person-to-person transmission is rare, pneumonia in patients sharing the same hospital room has been described.[7,8,12,13,16,17].
Little is still known about this pathogen’s resistance to drugs; in vitro sensitivity to erythromycin, fluoroquinolones, rifampin, aminoglycosides, imipenem, glycopeptides, as well as penicillin, erythromycin, vancomycin, rifampin and minocycline resistance, have been observed over the years. Also, its behaviour under exposure to tetracycline, clindamycin and cotrimoxazole may vary. Resistance is presumed to occur owing to PBP mutation, increased antibiotic degradation, and β-lactamase production, but further studies are evoked to shed some light on this obscure field. Intrinsic along with acquired resistance to penicillins and cephalosporins (including loss of sensitivity during therapy) have been described, so that the use of β-lactams is controversial and combination with intracellularly active compounds (such as rifampin, erythromycin, azithromycin, and ciprofloxacin) should be preferred (since intrahistiocytic survival remains a major virulence trait). Again, the use of linezolid, as well as that of β-lactam/β-lactamase inhibitor combination has been proposed. Treatment length should be based on frequent radiographic as well as clinical assessment, with prolonged (9-12 months) therapy being recommended in immunosuppressed hosts; instead, a 2- to 8-week course of two antibiotics seems to be enough for localised diseases (such as mild-moderate pneumonia and soft tissue abscess). In addition, some published works suggest that a 2- to 6-weeks induction with an intravenous compound (i.e. vancomycin, or a carbapenem, or an aminoglycoside) is needed in compromised patients, then combined with up to 6 months of oral azithromycin or rifampin. The infection can be faced by antibiotics alone, although surgical treatment may be beneficial for debulking extensive disease.[4,7,8,13,16,18,19].
This brief communication may add to the current knowledge about bloodstream and respiratory infections by rhodococci; also, it firstly reports misidentification of R. equi as Kocuria sp., thus emphasizing the risk of wrongly typing bacteria, unless genome-based methods are used. Again, we would suggest microbiologists to prolong cultures (not only those for fungi) up to ≥48 h, aiming to observe slowly growing bacteria that would be otherwise missed; but above all, we would increase clinicians’ awareness of this pathogen’s morbidity in compromised people.[13] In this context, we believe a deeper attention shoud be given to uncommon nosocomial agents of infections, to establish specific criteria for sensitivity testing, to investigate among their mechanisms of resistance, to better understand the epidemiology in the environment and within hospitals, and to increase the knowledge and consciousness of their clinical impact and pathogenic traits, that will otherwise remain fragmentary and incomplete.

Acknowledgements
We express our gratitude to Dr Alexandra V Yamshchikov, Emory University School of Medicine, Division of Infectious Diseases, Decatur, USA, for kindly giving us the permission to publish fig. 2 and 3, taken from Yamshchikov AV et al., Rhodococcus equi infection, Lancet Infect Dis 2010; 10: 350–359.


References
 
  1. Gelfand MS, Cleveland KO, Brewer SC. Rhodococcus equi pneumonia in a patient with fludarabine-treated chronic lymphocytic leukemia and CD4-lymphopenia. Am J Med Sci. 2010; 340: 80-1. PMid:20463575
  2. Meeuse JJ, Sprenger HG, van Assen S, Leduc D, Daenen SM, Arends JP, van der Werf TS Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia. Emerg Infect Dis. 2007; 13: 1942-3. PMid:18258054, PMCid:2876741
  3. Carpenter JL, Blom J. Corynebacterium equi pneumonia in a patient with Hodgkin's disease. Am Rev Respir Dis. 1976; 114: 235-9. PMid:937836
  4. Lortholary O, Mainardi JL, La Scola B, Gallais V, Frenaux P, Casassus P. Consecutive bacillary angiomatosis and Rhodococcus equi bacteremia during acute leukemia: zoonoses may cause fever in neutropenic patients. Clin Microbiol Infect. 2000; 6: 334-6. doi:10.1046/j.1469-0691.2000.00079.x PMid:11168145
  5. Sladek GG, Frame JN. Rhodococcus equi causing bacteremia in an adult with acute leukemia. South Med J. 1993; 86: 244-6. PMid:8434305
  6. Cid A, Jarque I, Salavert M, Martn G, Prez-Bells C, Sanz MA. Recurrent bacteremia caused by Rhodococcus equi in a non-neutropenic patient with acute myeloid leukemia in complete remission. Haematologica. 2002; 87: ECR03.
  7. Yamshchikov AV, Schuetz A, Lyon GM. Rhodococcus equi infection. Lancet Infect Dis. 2010; 10(5): 350-9. doi:10.1016/S1473-3099(10)70068-2
  8. Chen XY, Xu F, Xia JY, Cheng YS, Yang, Y. Bacteremia due to Rhodococcus equi: a case report and review of the literature. J Zhejiang Univ Sci B. 2009; 10: 933-6. doi:10.1631/jzus.B0920214 PMid:19946958   PMCid:2789529
  9. Savini V, Catavitello C, Masciarelli G, Astolfi D, Balbinot A, Bianco A, Febbo F, D'Amario C, D'Antonio D. Drug sensitivity and clinical impact of members of the genus Kocuria. J Med Microbiol. 2010; 59(Pt 12): 1395-1402. doi:10.1099/jmm.0.021709-0 PMid:20884772
  10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility testing. 8th informational supplement. Wayne, PA: National Committee for Clinical Laboratory Standards; 2003. Approved Standard M2-27.
  11. von Bargen K, Haas A. Molecular and infection biology of the horse pathogen Rhodococcus equi. FEMS Microbiol Rev. 2009; 33: 870-91. doi:10.1111/j.1574-6976.2009.00181.xPMid:19453748
  12. Speck D, Koneth I, Diethelm M, Binet I. A pulmonary mass caused by Rhodococcus equi infection in a renal transplant recipient. Nat Clin Pract Nephrol. 2008; 4:398-403. doi:10.1038/ncpneph0833 PMid:18506169
  13. Tuon FF, Siciliano RF, Al-Musawi T, Rossi F, Capelozzi VL, Gryschek RC, et al. Rhodococcus equi bacteremia with lung abscess misdiagnosed as Corynebacterium: a report of 2 cases. Clinics (Sao Paulo). 2007; 62:795-8.
  14. Ben-Ami R, Navon-Venezia S, Schwartz D, Schlezinger Y, Mekuzas Y, Carmeli Y. Erroneous reporting of coagulase-negative staphylococci as Kocuria spp. by the Vitek 2 system. J Clin Microbiol. 2005; 43:1448-50. doi:10.1128/JCM.43.3.1448-1450.2005 PMid:15750130 PMCid:1081215
  15. Boudewijns M, Vandeven J, Verhaegen J, Ben-Ami R, Carmeli Y. Vitek 2 automated identification system and Kocuria spp. kristinae. J Clin Microbiol. 2005; 43:5832. doi:10.1128/JCM.43.11.5832.2005 PMid:16272536 PMCid:1287845
  16. Sistla S, Karthikeyan S, Biswas R, Parija SC, Patro DK. Acute osteomyelitis caused by Rhodococcus equi in an immunocompetent child. Indian J Pathol Microbiol. 2009; 52:263-4. doi:10.4103/0377-4929.48940
  17. Matsushita H, Hanayama N, Hobo K, Kuba K, Takazawa A. Infectious endocarditis caused by Rhodococcus equi. Ann Thorac Surg. 2010; 89:957-9. doi:10.1016/j.athoracsur.2009.08.053 PMid:20172165
  18. Borghi E, La Francesca M, Gazzola L, Marchetti G, Zonato S, Foa P, d'Arminio Monforte A, Morace G. Rhodococcus equi infection in a patient with spinocellular carcinoma of unknown origin. J Med Microbiol. 2008; 57(Pt 11): 1431-3. doi:10.1099/jmm.0.2008/002048-0 PMid:18927425
  19. Rahamat-Langendoen JC, van Meurs M, Zijlstra JG, Lo-Ten-Foe JR. Disseminated Rhodococcus equi infection in a kidney transplant patient without initial pulmonary involvement. Diagn Microbiol Infect Dis. 2009; 65:427-30. doi:10.1016/j.diagmicrobio.2009.08.004 PMid:19762194



Abstract views:
141

Views:
PDF
108
HTML
6923

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185